Drugs / MOv-PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00019136 | Feb 1997 → ? | ovarian cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOv-PBL | “retroviral transduction with antiovarian cancer MOv-gamma chimeric receptor gene (MOv-PBL). MOv-PBL are then reinfused IV over 30-60 minutes” NCT00019136 ↗ |
| Action | Deplete | “gene-modified to recognize and kill ovarian cancer cells” NCT00019136 ↗ |
| Modality | Cell therapy | “gene-modified lymphocytes (MOv-PBL)” NCT00019136 ↗ |
| Route | Intravenous | “MOv-PBL are then reinfused IV over 30-60 minutes” NCT00019136 ↗ |